Foster, Jason MSleightholm, RichardSmith, LynetteCeelen, WimDeraco, MarcelloYildirim, YusufLevine, EdwardMuñoz-Casares, CristobalGlehen, OlivierPatel, AsishEsquivel, Jesus2023-01-252023-01-252016-10-28Foster JM, Sleightholm R, Smith L, Ceelen W, Deraco M, Yildirim Y, et al. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. J Surg Oncol. 2016 Dec;114(7):779-784http://hdl.handle.net/10668/13041Background: Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum-taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. Methods: The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology. Overall survival was analyzed according to PSDSS as well as the timings and agents used during CRS/HIPEC. Results: Median survival for all 1,051 patients was 73.4 months. PSDSS information was available for 553 patients. Survival correlated negatively with PSDSS (P < 0.001). Furthermore, combining PSDSS scores into I/II and III/IV described two distinct patient populations with vastly different outcomes, 100 versus 55 months, respectively (P < 0.001). Multivariate analysis failed to describe any differences between timings of HIPEC or chemotherapy agents used. Conclusion: PSDSS was capable of identifying a better surviving patient population in advanced-stage OEC. While randomized trials to evaluate the benefit of HIPEC are needed, the PSDSS may be a useful tool for selecting and stratifying OEC patients in clinical trials.enPSDSSOEC ovarian epithelial cancerCRSHIPECHyperthermic Intraperitoneal ChemotherapyCarcinoma, Ovarian EpithelialCytoreduction Surgical Proceduresresearch article30295939Restricted AccessQuimioterapia intraperitoneal hipertérmicaProtocolos de quimioterapia combinada antineoplásicaSupervivencia sin enfermedadTerapia neoadyuvanteHepatectomía10.1002/jso.246031096-9098https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.24603